We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

131 hedge funds and large institutions have $652M invested in Sciclone Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

206% more capital invested

Capital invested by funds: $213M → $652M (+$439M)

13% more funds holding

Funds holding: 116131 (+15)

12% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

35% less call options, than puts

Call options by funds: $608K | Put options by funds: $939K

Holders
131
Holders Change
+15
Holders Change %
+12.93%
% of All Funds
3.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
47
Reduced
42
Closed
8
Calls
$608K
Puts
$939K
Net Calls
-$331K
Net Calls Change
-$168K
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
1
Americafirst Capital Management
California
$351M +$325K +40,120 New
Franklin Resources
2
Franklin Resources
California
$33.8M -$3.43M -423,300 -10%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$21M +$578K +71,348 +3%
BFA
4
BlackRock Fund Advisors
California
$18M +$1.4M +172,422 +9%
BIT
5
BlackRock Institutional Trust
California
$17.9M -$1.03M -127,076 -6%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$17.7M +$269K +33,244 +2%
LSV Asset Management
7
LSV Asset Management
Illinois
$16M -$4.19M -517,212 -22%
Vanguard Group
8
Vanguard Group
Pennsylvania
$15.9M +$2.83M +350,111 +24%
NCM
9
Nantahala Capital Management
Connecticut
$12.2M -$3.89M -480,842 -26%
SI
10
Sensato Investors
California
$12.1M +$11.2M +1,380,462 New
State Street
11
State Street
Massachusetts
$7.97M -$863K -106,610 -10%
NI
12
Numeric Investors
Massachusetts
$7.56M +$5.48M +677,314 +365%
MCM
13
McKinley Capital Management
Alaska
$7.42M +$6.86M +847,579 New
QI
14
QS Investors
New York
$6.08M +$5.61M +693,581 New
OAM
15
Oxford Asset Management
United Kingdom
$5.33M -$886K -109,478 -15%
Northern Trust
16
Northern Trust
Illinois
$4.93M -$180K -22,278 -4%
RFC
17
Russell Frank Company
Washington
$3.79M +$1.44M +178,388 +70%
Morgan Stanley
18
Morgan Stanley
New York
$3.25M +$15.6K +1,927 +0.5%
BIM
19
Bogle Investment Management
Massachusetts
$3.21M +$1.16M +142,966 +64%
Charles Schwab
20
Charles Schwab
California
$3.17M +$1.31M +161,480 +81%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$3.05M -$690K -85,212 -20%
Wellington Management Group
22
Wellington Management Group
Massachusetts
$2.86M +$519K +64,108 +24%
Bank of New York Mellon
23
Bank of New York Mellon
New York
$2.85M -$5.53K -683 -0.2%
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$2.82M +$1.03M +126,937 +65%
CAM
25
ClariVest Asset Management
California
$2.51M +$3.18K +393 +0.1%

SCLN Hedge Fund Activity: Q4 2014 in Review

131 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2014, worth a combined $652M — up 206% from $213M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SCLN positions and 8 closed out — a net gain of 17 holders — while 47 added to existing stakes and 42 trimmed.

The largest buyer was McKinley Capital Management, opening a new position worth an estimated $6.86M. The largest seller was LSV Asset Management, cutting an estimated $4.19M.

  • 131 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2014, up from 116 in Q3 2014.
  • Funds reported $652M of Sciclone Pharmaceuticals Inc stock for Q4 2014, up 206% quarter-over-quarter.
  • 25 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2014 and 8 closed out, a net change of +17 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2014 was McKinley Capital Management, an estimated $6.86M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2014 was LSV Asset Management, an estimated $4.19M sold.

Based on aggregated 13F filings for Q4 2014.